Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057 Meeting Abstract
| Authors: | De Wit, R.; Kulkarni, G. S.; Uchio, E. M.; Krieger, L. E. M.; Boormans, J. L.; Roumiguié, M.; Singer, E. A.; Bajorin, D. F.; Kamat, A. M.; Grivas, P.; Seo, H. K.; Nishiyama, H.; Konety, B. R.; Nam, K.; Kapadia, E.; Frenkl, T. L.; Balar, A. V. |
| Abstract Title: | Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057 |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 271s |
| Language: | English |
| ACCESSION: | WOS:000487345805355 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.4530 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4530 -- Source: Wos |
